RadioClash offers enhanced electroporation therapy specifically designed for treating liver, pancreatic, and bone cancers. This minimally invasive approach provides effective treatment with faster recovery times and reduced costs compared to traditional cancer therapies.
Funding
$807.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer therapies for liver, pancreatic, and bone cancers can be invasive, costly, and associated with long recovery times. These factors can significantly impact patient quality of life and treatment outcomes.
Solution
RadioClash provides enhanced electroporation therapy as a minimally invasive treatment option for liver, pancreatic, and bone cancers. This approach aims to deliver effective cancer treatment while promoting faster recovery times and potentially reducing overall treatment costs compared to conventional methods. By targeting cancerous cells directly, RadioClash seeks to improve patient outcomes and quality of life.
Target Audience
The primary target audience includes oncologists and patients seeking alternative or complementary treatment options for liver, pancreatic, and bone cancers.
Features
- Minimally invasive procedure, reducing trauma to surrounding tissues
- Enhanced electroporation technology for targeted cancer cell destruction
- Designed for treating liver, pancreatic, and bone cancers